{"id":28479,"date":"2020-05-19T08:00:45","date_gmt":"2020-05-19T06:00:45","guid":{"rendered":"http:\/\/www.veeva.com\/eu\/?post_type=resources&p=28479"},"modified":"2022-07-16T16:48:08","modified_gmt":"2022-07-16T14:48:08","slug":"veeva-enables-cros-to-build-studies-faster-with-vault-edc","status":"publish","type":"resources","link":"https:\/\/www.veeva.com\/eu\/resources\/veeva-enables-cros-to-build-studies-faster-with-vault-edc\/","title":{"rendered":"Veeva Enables CROs to Build Studies Faster with Vault EDC"},"content":{"rendered":"

5 of the top 7 CROs join Vault CDMS CRO partner program
to speed the deployment of high-quality clinical trials
\n<\/em><\/p>\n

BARCELONA \u2014 2020 Veeva R&D Summit, Europe \u2014 19 May, 2020 <\/strong> Veeva Systems<\/a> (NYSE:VEEV) today announced a new partner program to help CROs build studies faster using Veeva Vault EDC<\/a>. As part of the CRO partner program, CROs are trained and receive best practices configuring casebooks directly from a protocol with Studio, a new design innovation in Vault EDC to reduce study build times. Ten global CROs, including 5 of the top 7 largest CROs, are already part of the program<\/a> to configure studies for sponsors.<\/p>\n

Vault EDC enables an agile design approach for configuring casebooks by making it easier for clinical programmers to reuse forms, components, and rules during the database build. CROs can collaborate more effectively with sponsors during the build process and make changes to the case report form in real-time. This significantly reduces the time and effort of clinical programmers to build a study database so that data collection can start sooner.<\/p>\n

With the CRO partner program, Veeva is enabling a growing network of CROs trained to configure casebooks in Vault EDC. CROs receive 2-4 weeks of training, best practices in agile design, and mentoring during their first casebook build. CROs are fully trained to build complex studies and make mid-study changes quickly with Vault EDC.<\/p>\n

\u201cWe are making it easier for CROs to build quality studies and get them up and running faster for sponsors,\u201d said Richard Young, vice president of strategy for Veeva Vault CDMS<\/a>. \u201cSponsors can have the confidence that CROs are ready to configure the most complex studies and deploy study amendments faster than ever before with Veeva Vault EDC.\u201d<\/p>\n

In other news, Veeva today announced MyVeeva<\/a>, a multichannel patient portal for virtual visits and patient-centric trials, and Veeva Vault Site Connect<\/a>, an application that connects sponsors and clinical research sites during studies. Both are part of the Veeva Clinical Network, a set of solutions that enables sponsors, sites, and patients to share and view information and accelerate clinical research.<\/p>\n

Learn more about Vault EDC and Vault CDMS at the online Veeva R&D Summit, 19-20 and 26 May, 2020. CROs interested in hearing more about the partner program can contact info@veeva.com<\/a>.<\/p>\n

Additional Information<\/strong>
\nConnect with Veeva on LinkedIn: linkedin.com\/company\/veeva-systems<\/a>
\nFollow @veevasystems on Twitter: twitter.com\/veeva_eu<\/a>
\nLike Veeva on Facebook: facebook.com\/veevasystems<\/a><\/p>\n

About Veeva Systems<\/strong>
\nVeeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 850 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com\/eu<\/a>.<\/p>\n

Forward-looking Statements<\/strong>
\nThis release contains forward-looking statements, including the market demand for and acceptance of Veeva\u2019s products and services, the results from use of Veeva\u2019s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-K for the period ended January 31, 2020. This is available on the company\u2019s website at veeva.com<\/a> under the Investors section and on the SEC\u2019s website at sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.<\/p>\n

###<\/p>\n

Contact:<\/strong>
\nVeeva Systems
\npr@veeva.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

5 of top 7 CROs join partner program to speed deployment of trials.<\/p>\n","protected":false},"featured_media":28504,"parent":0,"template":"","class_list":["post-28479","resources","type-resources","status-publish","has-post-thumbnail","hentry","resource-area-20-clinical-data-management","resource-product-20-edc","resource-type-news-press-release"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t